Oriola Oyj Series B (0NES) fair value: what the stock is really worth
As of Oct 2, 2026: fair value of Oriola Oyj Series B €0.53, price €0.82, upside -35.6%, quality 52 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Oriola Oyj Series B for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.
How to read this chart
60‑month range €0.7602 – €1.83 · fair‑value band €0.5200 – €0.5400 · the €0.8230 price screens above the €0.5300 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). 1 fiscal year is left out: there the valuation rested on only a fraction of the usual models. Dashed = 300-day average. As of Sep 24, 2026.
Follow Oriola Oyj Series B in your weekly email
Every Wednesday you see whether Oriola Oyj Series B is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Oriola Oyj engages in the wholesale of pharmaceuticals and health products in Sweden, Finland, and internationally. The company distributes vitamins, food and food supplements, sports nutrients, wound care, beauty, and makeup related products; vaccines; and over-the-counter products.
Show more
Oriola Oyj engages in the wholesale of pharmaceuticals and health products in Sweden, Finland, and internationally. The company distributes vitamins, food and food supplements, sports nutrients, wound care, beauty, and makeup related products; vaccines; and over-the-counter products. In addition, it provides pharmaceutical logistics; special licensed medicine importing, dose dispensing, and research pharmacy services; and commercial data, clinical trial, regulatory affairs and quality, medical and scientific affairs, market access and tenders, real world evidence, sales support, medical translation, pharmacovigilance and medical information, and patient support services. Further, the company provides advisory services. It serves pharmaceutical companies, pharmacies, veterinarians, hospitals, healthcare providers, special stores, retailers, and e-commerce companies. The company was founded in 1907 and is headquartered in Espoo, Finland.
Stock analysis
Oriola Oyj Series B (0NES) currently trades at €0.8230, while our model-based Fair Value estimate is €0.5300, 35.6% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the DCF Models group reads highest at a median of €2.67 per share, and 8 of the 13 models we run sit above the €0.8230 price.
Bear case: the Asset-Based group reads lowest at €0.3700, and 5 of the 13 models stay below the price. Evidence for this calculation is medium.
Scenario range: €0.5200 (bear) to €0.5400 (bull), the price of €0.8230 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 52/100 (solid quality), in the Healthcare sector.
Weak Growth: Revenue growth is weak: less than 2 % a year.
Oriola Oyj Series B reported revenue of €1.9B in FY2025 versus €1.5B in FY2021, a compound +7.0%/yr. Reported net income was −€27.2M in FY2025.
Key figures
Market cap €171M · P/E ratio 0.1 · P/S ratio 0.09 · EPS (TTM) €0.1170 · Dividend yield 3.6% · Net margin −1.4% · Return on equity −19.1% · Return on assets (EBIT) 2.7%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 43 out of 100 (low confidence).
What moves the price
The share trades about 32% below its 52-week high and at its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at −36%, 0NES screens richer than that median.
Fair Value models
Bear €0.5200Fair Value €0.5300Bull €0.5400
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 9 months old). Earnings retained since then (€0.0658 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.31/100
Revenue growth is weak: less than 2 % a year.
Revenue growth 1 year
+13.5%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+7.4%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+1.1%
Start year 2020 (pandemic). Over 10 years: +1.6% a year
Revenue growth 19 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+5.7%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
1.9% (2020) → 0.1% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed
Growth Forecast
Little optimism in the price
The price assumes less growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
−35.1%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (figures in EUR, euro area: IMF forecast 2.2% a year to 2030, 2.6% from 2016 to 2025) that is about −36.4% a year for the price.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Pharmaceutical Retailers · 56 stocks
Beats the industry median on 4/13 measures
Overall it trails its industry peers.
Valuation
Quality Score52 · Below median
Fair Value upside−35.6% · Bottom 25%
Profitability
Return on assets0.3% · Below median
Net margin (TTM)−1.0% · Bottom 25%
Operating margin (TTM)1.2% · Below median
Growth and dividend
Revenue growth1.8% · Below median
Dividend yield (TTM)3.6% · Above median
Balance sheet
Debt / equity0.65× · Highest 25%
Valuation Multiplesvs Pharmaceutical Retailers median · lower = cheaper
P/E (TTM)0.1× · Cheapest 25%
P/B1.91× · Pricier than median
P/S (TTM)0.10× · Cheapest 25%
P/FCF3.4× · Cheapest 25%
EV/EBITDA8.4× · Pricier than median
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 42
FUTURE (revenue growth)9· sector 13
PAST (return on equity)0· sector 22
HEALTH (low debt)67· sector 96
DIVIDEND (yield)73· sector 65
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Oriola Oyj Series B Fair Value". https://www.fairvalue-calculator.com/stock/0NES
Frequently asked questions
Is Oriola Oyj Series B (0NES) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of €0.5300 versus a price of €0.8230, about −36% upside (overvalued).
What is the fair value of 0NES?
Our model-based fair value for Oriola Oyj Series B is €0.5300 (as of Sep 24, 2026), built from audited fundamentals. The current price: €0.8230.
What is the quality score of 0NES?
Oriola Oyj Series B has a Quality Score of 52/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Oriola Oyj Series B (0NES)?
Our model-based price target is the fair value of €0.5300 (as of Sep 24, 2026) from 13 valuation models. Cautious scenario €0.5200, optimistic scenario €0.5400. It is a calculation from audited fundamentals, not an analyst target.
What is the Oriola Oyj Series B stock forecast for 2026?
Our models put fair value at €0.5300, about −36% upside versus a price of €0.8230 (overvalued). Cautious scenario €0.5200, optimistic scenario €0.5400. The calculation is refreshed regularly with new filings.
What is the revenue of Oriola Oyj Series B (0NES)?
Oriola Oyj Series B reported trailing-twelve-month revenue of about €1.9B (latest available figure, as of Sep 24, 2026).
Does Oriola Oyj Series B pay a dividend?
Oriola Oyj Series B currently shows a dividend yield of about 3.65% relative to its recent price (as of Sep 24, 2026).
What growth is priced into Oriola Oyj Series B (0NES)?
For today's price to be fair in a discounted-cash-flow model, Oriola Oyj Series B would have to grow free cash flow by -35.1 % per year for five years (discount rate 11.8 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +1.1 % per year. As of Sep 24, 2026.
What discount rate (WACC) does the fair value of 0NES use?
Our models discount Oriola Oyj Series B at 11.8 %: a base by market capitalisation (micro), damped by beta 0.48, country premium for United Kingdom. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Oriola Oyj Series B that is -35.1 % per year a year over ten years, using the same discount rate (11.8 %) and the same formula as our fair value.
How much growth has Oriola Oyj Series B (0NES) delivered so far?
Over the past 5 years revenue at Oriola Oyj Series B grew +1.1 % a year. The price currently implies -35.1 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Oriola Oyj Series B (0NES) growing?
The median revenue growth in the sector is +9.3 % a year. That is the yardstick for the growth priced into Oriola Oyj Series B (-35.1 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Oriola Oyj Series B (0NES)?
The free-cash-flow yield on the price is 31.79 %: that much free cash flow Oriola Oyj Series B produces per unit of market value. When it exceeds the discount rate of our models (11.8 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Oriola Oyj Series B (0NES)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Oriola Oyj Series B it is €0.5300 per share (as of Sep 24, 2026), against a price of €0.8230. It is the blended result of 13 valuation models (cash flow, earnings, asset, dividend).
Is Oriola Oyj Series B stock overvalued or undervalued in 2026?
As of Sep 24, 2026, 0NES trades above its calculated fair value: price €0.8230, fair value €0.5300, a gap of about −36% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 0NES?
No. The price is what the market pays today (€0.8230); the fair value is what the company's own numbers justify (€0.5300). For Oriola Oyj Series B the two are €0.2930 per share apart. That gap is exactly why we show both numbers side by side.
How much is Oriola Oyj Series B worth?
The market values Oriola Oyj Series B at about €171M (market capitalisation, as of Sep 24, 2026). Per share that is €0.8230; our models calculate a fair value of €0.5300 per share.
What do the bullish and bearish scenarios say about 0NES?
Our models span a range for Oriola Oyj Series B: cautious scenario €0.5200, base €0.5300, optimistic €0.5400 per share (as of Sep 24, 2026, price €0.8230). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 0NES?
Oriola Oyj Series B trades at a price-to-earnings ratio of 0.1 (as of Sep 24, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of €0.5300 is built from several models across several years. Other multiples: P/B 1.9, P/S 0.1, EV/EBITDA 8.4.
How solid is the balance sheet of Oriola Oyj Series B (0NES)?
Balance-sheet figures for Oriola Oyj Series B (as of Sep 24, 2026): return on equity −19.1%, debt of 0.65 per unit of equity. They feed the Quality Score of 52/100, which measures business quality independently of the share price.
How far is 0NES from its 52-week high?
Oriola Oyj Series B trades at €0.8230, about 32% below its 52-week high of €1.21 and at the low of €0.8230 (as of Oct 2, 2026). Distance from the high says nothing about value: that is what the fair value of €0.5300 is for.
Which stocks are comparable to Oriola Oyj Series B?
From the same area (Healthcare) we also value Alibaba Health Information Technology Limited, Yifeng Pharmacy Chain Co, DaShenLin Pharmaceutical Group, LBX Pharmacy Chain Joint Stock Company, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Oriola Oyj Series B stock attractive at the current price?
The data as of Sep 24, 2026: price €0.8230, calculated fair value €0.5300 (−36%), Quality Score 52/100, from 13 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 0NES calculated?
We run Oriola Oyj Series B through 13 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of €0.5300, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. Oriola Oyj Series B itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Oriola Oyj Series B (0NES)?
The closing price on Oct 2, 2026 was €0.8230. Our model-based fair value is €0.5300, about −36% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Oriola Oyj Series B right now?
The price sits above even our optimistic bull case (€0.5400). The favourable scenario is already priced in. Solid but not exceptional quality (52/100) and above fair value, neither a clear bargain nor a standout compounder. The models converge in a tight band (€0.5200 to €0.5400), unusually little disagreement for a valuation.
Key figures of Oriola Oyj Series B
How large is the market capitalisation of Oriola Oyj Series B (0NES)?
The market capitalisation of Oriola Oyj Series B is €171M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Oriola Oyj Series B (0NES)?
The price-to-sales ratio of Oriola Oyj Series B is 0.09 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Oriola Oyj Series B (0NES)?
Earnings per share at Oriola Oyj Series B are €0.1170 (price ÷ EPS = P/E 0.1). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Oriola Oyj Series B (0NES)?
The dividend yield of Oriola Oyj Series B is 3.6% (payout 25.6%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Oriola Oyj Series B (0NES)?
The net margin of Oriola Oyj Series B is −1.4% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Oriola Oyj Series B (0NES)?
The return on equity (ROE) of Oriola Oyj Series B is −19.1% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Oriola Oyj Series B (0NES)?
On an EBIT basis the return on assets of Oriola Oyj Series B is 2.7% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Oriola Oyj Series B (0NES)?
The operating margin of Oriola Oyj Series B is 1.2% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Oriola Oyj Series B (0NES)?
Revenue at Oriola Oyj Series B is growing +1.8% versus a year earlier (3y avg +7.4%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Oriola Oyj Series B (0NES)?
Earnings per share at Oriola Oyj Series B are growing −90.0% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net cash does Oriola Oyj Series B (0NES) hold?
Oriola Oyj Series B holds more cash than debt, €73.9M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch Oriola Oyj Series B in the live analysis
One click puts Oriola Oyj Series B on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
